Expression of terminally glycosylated calcitonin receptor - Like receptor in uterine leiomyoma: Endothelial phenotype and association with microvascular density

Clinical Cancer Research

Volumn 12, Issue 19, 2006, Pages 5648-5658

  Nikitenko, Leonid L ^a,b,c   Cross, Tanya ^a   Campo, Leticia ^a   Turley, Helen ^a   Leek, Russell ^a   Manek, Sanjiv ^b   Bicknell, Roy ^b   Rees, Margaret C P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; CALCITONIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; MESSENGER RNA; RECEPTOR ACTIVITY MODIFYING PROTEIN 2;

ADULT; ANGIOGENESIS; ARTICLE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEGLYCOSYLATION; FEMALE; GLYCOSYLATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MYOMETRIUM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; UTERUS MYOMA; VASCULAR ENDOTHELIUM;

ADRENOMEDULLIN; ADULT; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSYLATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEIOMYOMA; MEMBRANE PROTEINS; MICROCIRCULATION; MIDDLE AGED; MYOMETRIUM; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RECEPTORS, CALCITONIN; UTERINE NEOPLASMS;

EID: 33750379765     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0852     Document Type: Article

References (49)

1. Folkman J. Tumour angiogenesis. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine. Ontario: Decker; 2000. p. 132-52.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004;350:2335-42.
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
5. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
6. LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002;8:913-7.
7. Flake GP, Andersen J, Dixon D. Etioligy and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2002;111:1037-54.
8. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995;80:1853-8.
9. Hague S, Zhang L, Oehler MK, et al. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin Cancer Res 2000;3:2808-14.
10. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60.
11. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138-67.
12. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002;54:233-46.
13. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2002;2:38-47.
14. Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002;21:2815-21.
15. Ouafik L, Sauze S, Boudouresque F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002;160:1279-92.
16. Martinez A, Vos M, Guedez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002;94:1226-37.
17. Nikitenko LL, Fox SB, Kehoe S, Rees MCP, Bicknell R. Adrenomedullin and tumor angiogenesis. Br J Cancer 2006;94:1-7.
18. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-9.
19. Sexton PM, Albiston A, Morfis M, Tilakaratne M. Receptor activity modifying proteins. Cell Signal 2001;13:73-83.
20. Hilairet S, Foord SM, Marshall FH, Bouvier M. Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J Biol Chem 2001;276:29575-81.
21. Kim W, Moon SO, Sung MJ, et al. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J 2003;17:1937-9.
22. Fernandez-Sauze S, Delfino C, Marbrouk K, et al. Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004;108:797-804.
23. Nikitenko LL, Blucher N, Fox SB, Bicknell R, Smith DM, Rees MCP. Adrenomedullin and CGRP interact with endogenous calcitonin receptor-like receptor in endothelial cells and induce its desensitisation via different mechanisms. J Cell Sci 2006;119:910-22.
24. Nikitenko LL, Brown NS, Smith DM, MacKenzie IZ, Bicknell R, Rees MC. Differential and cell-specific expression of calcitonin receptor-like receptor and receptor activity modifying proteins in the human uterus. Mol Hum Reprod 2001;7:655-64.
25. Hagner S, Stahl U, Knoblauch B, McGregor GP, Lang RE. Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues. Cell Tissue Res 2002;310:41-50.
26. LeCouter J, Ferrara N. EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. Trends Cardiovasc Med 2003;13:276-82.
27. Vasillatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 2003;100:4903-8.
28. Nikitenko LL, Smith DM, Bicknell R, Rees MC. Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J 2003;17:1499-501. Full-length article is available from: http://www.fasebj.org/ cgi/reprint/02-0993fjev1.pdf.
29. Nikitenko LL, MacKenzie IZ, Rees MCP, Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000;6:811-9.
30. Kaipainen A, Korhonen J, Pajusola K, et al. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med 1993;178:2077-88.
31. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001;69:135-44.
32. Kuwasako K, Shimekake Y, Masuda M, et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem 2000;275:29602-9
33. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407. 242-8.
34. Carmeliet P. Angiogenesis in life, disease, and medicine. Nature 2005;438:932-6.
35. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept 2003;112:175-83.
36. Auerbach R, Alby L, Morrissey LW, Tu M, Joseph J. Expression of organ-specific antigens on capillary endothelial cells. Microvasc Res 1985;29:401-11.
37. Fox SB, Harris AL. Histological quantitation of tumor angiogenesis. APMIS 2004;112:413-30.
38. Casey R, Rogers PA, Vollenhoven BJ. An immunohistochemical analysis of fibroid vasculature. Hum Reprod 2000;15:1469-75.
39. Poncelet C, Madelenat P, Feldmann G, Walker F, Darai E. Expression of von Willebrand's factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas. Fertil Steril 2002;78:581-6.
40. Koenig JA, Edwardson JM. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 1997;18:276-87.
41. Gokdeniz R, Mizrak B, Ozen S, Bazoglu N. Endothelial nitric oxide synthase expression in leiomyoma and parental myometrium. Gynecol Obstet Invest 2000;49:132-6.
42. Gargett CE, Bucak K, Zaitseva M, et al. Estrogen receptor-α and -β expression in microvascular endothelial cells and smooth muscle cells of myometrium and leiomyoma. Mol Hum Reprod 2002;8:770-5.
43. Hay DL, Smith DM, Poyner D. Desensitisation of adrenomedullin and CGRP receptors. Regul Pept 2003;112:139-45.
44. Bomberger JM, Spielman WS, Hall CS, Weinmann EJ, Paramesarwaran N. Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1. J Biol Chem 2005;280:23926-35.
45. Prado MA, Evans-Bain B, Oliver KR, Dickerson IM. The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor signal transduction. Peptides 2001;11:1773-81.
46. Pokabla MJ, Dickerson IM, Papka RE. Calcitonin gene-related peptide-receptor component protein expression in the uterine cervix, lumbosacral spinal cord, and dorsal root ganglia. Peptides 2002;23:507-14.
47. Penn RB, Pronin AN, Benovic JL. Regulation of G-protein coupled receptor kinases. Trends Cardiovasc Med 2000;10:81-9.
48. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension Nat Med 2005;11:952-8.
49. Aiyar N, Disa J, Dang K, Pronin AN, Benovic JL, Nambi P. Involvement of G protein-coupled receptor kinase-6 in desensitization of CGRP receptors. Eur J Pharmacol 2000;403:1-7.